Evidence map›Paper›PMID 28038459›Full record

ArticleOncotarget2017

The Netrin-4/ Neogenin-1 axis promotes neuroblastoma cell survival and migration.

Andrea A Villanueva, Paulina Falcón, Natalie Espinoza, Luis Solano R, Luis A Milla, Esther Hernandez-SanMiguel, Vicente A Torres, Pilar Sanchez-Gomez, Verónica Palma

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 26 citations in OpenAlex.

  1. Crosstalk in Skin: Loss of Desmoglein 1 in Keratinocytes Inhibits BRAFThe Journal of investigative dermatology · 2025
    Article
  2. Article
  3. Research progress of the netrins and their receptors in cancer.Journal of cellular and molecular medicine · 2024
    Review
  4. Hepatic Expression of NTN4 and Its Receptors in Patients with Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2023
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Andrea A VillanuevaLaboratory of Stem Cells and Developmental Biology, Faculty of Sciences, Universidad de Chile, Santiago, Chile.
Paulina FalcónLaboratory of Stem Cells and Developmental Biology, Faculty of Sciences, Universidad de Chile, Santiago, Chile.
Natalie EspinozaLaboratory of Stem Cells and Developmental Biology, Faculty of Sciences, Universidad de Chile, Santiago, Chile.
Luis Solano RLaboratory of Stem Cells and Developmental Biology, Faculty of Sciences, Universidad de Chile, Santiago, Chile.
Luis A MillaLaboratory of Stem Cells and Developmental Biology, Faculty of Sciences, Universidad de Chile, Santiago, Chile.
Esther Hernandez-SanMiguelNeurooncology Unit, Chronic Disease Program, ISCIII, Madrid, Spain.
Vicente A TorresInstitute for Research in Dental Sciences and Advanced Center for Chronic Diseases (ACCDiS), Faculty of Dentistry, Universidad de Chile, Santiago, Chile.
Pilar Sanchez-GomezNeurooncology Unit, Chronic Disease Program, ISCIII, Madrid, Spain.
Verónica PalmaLaboratory of Stem Cells and Developmental Biology, Faculty of Sciences, Universidad de Chile, Santiago, Chile.
University of Chile · CLInstituto de Salud Carlos III · ESAdvanced Center for Chronic Diseases · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neogenin-1 (NEO1) is a transmembrane receptor involved in axonal guidance, angiogenesis, neuronal cell migration and cell death, during both embryonic development and adult homeostasis. It has been described as a dependence receptor, because it promotes cell death in the absence of its ligands (Netrin and Repulsive Guidance Molecule (RGM) families) and cell survival when they are present. Although NEO1 and its ligands are involved in tumor progression, their precise role in tumor cell survival and migration remain unclear. Public databases contain extensive information regarding the expression of NEO1 and its ligands Netrin-1 (NTN1) and Netrin-4 (NTN4) in primary neuroblastoma (NB) tumors. Analysis of this data revealed that patients with high expression levels of both NEO1 and NTN4 have a poor survival rate. Accordingly, our analyses in NB cell lines with different genetic backgrounds revealed that knocking-down NEO1 reduces cell migration, whereas silencing of endogenous NTN4 induced cell death. Conversely, overexpression of NEO1 resulted in higher cell migration in the presence of NTN4, and increased apoptosis in the absence of ligand. Increased apoptosis was prevented when utilizing physiological concentrations of exogenous Netrin-4. Likewise, cell death induced after NTN4 knock-down was rescued when NEO1 was transiently silenced, thus revealing an important role for NEO1 in NB cell survival. In vivo analysis, using the chicken embryo chorioallantoic membrane (CAM) model, showed that NEO1 and endogenous NTN4 are involved in tumor extravasation and metastasis. Our data collectively demonstrate that endogenous NTN4/NEO1 maintain NB growth via both pro-survival and pro-migratory molecular signaling.

Indexed as

Cell MovementAnimalsApoptosisCell Line, TumorCell SurvivalChick EmbryoChorioallantoic MembraneGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateNeoplasm InvasivenessNerve Tissue ProteinsNetrinsNeuroblastomaReceptors, Cell SurfaceRNA InterferenceNEO1 protein, humanNerve Tissue ProteinsNetrinsNTN4 protein, humanReceptors, Cell Surfacecell migrationmetastasisNeogenin-1Netrin-4survival

Identifiers

PMID28038459
PMCPMC5354769
OpenAlexW2561056152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.